71 related articles for article (PubMed ID: 38590108)
1. Phenotyping Hepatic Immune-Related Adverse Events in the Setting of Immune Checkpoint Inhibitor Therapy.
Feldman TC; Kaplan DE; Lin A; La J; Lee JSH; Aljehani M; Tuck DP; Brophy MT; Fillmore NR; Do NV
JCO Clin Cancer Inform; 2024 May; 8():e2300159. PubMed ID: 38728613
[TBL] [Abstract][Full Text] [Related]
2. Digestive Toxicities Secondary to Immune Checkpoint Inhibition Therapy - Reports of Rare Events. A Systematic Review.
Radulescu L; Crisan D; Grapa C; Radulescu D
J Gastrointestin Liver Dis; 2021 Dec; 30(4):506-516. PubMed ID: 34752584
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenterstudy.
Nagao K; Sakai A; Tsumura H; Iemoto T; Hirata Y; Hori H; Ogisu K; Kakuyama S; Ikegawa T; Hirata T; Ezaki T; Furumatsu K; Yamanaka K; Kato T; Fujigaki S; Tanaka H; Yagi Y; Tanaka T; Kobayashi T; Masuda A; Shiomi H; Kodama Y
J Gastroenterol; 2024 May; 59(5):424-433. PubMed ID: 38421473
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review.
Taherian M; Chatterjee D; Wang H
J Clin Transl Pathol; 2022 Sep; 2(3):83-90. PubMed ID: 36618338
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of immune mediated liver injury from checkpoint inhibitors.
Likhitsup A; Fontana RJ
Curr Opin Gastroenterol; 2024 May; 40(3):164-171. PubMed ID: 38375823
[TBL] [Abstract][Full Text] [Related]
6. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
[TBL] [Abstract][Full Text] [Related]
8. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review.
Dougan M; Wang Y; Rubio-Tapia A; Lim JK
Gastroenterology; 2021 Mar; 160(4):1384-1393. PubMed ID: 33080231
[TBL] [Abstract][Full Text] [Related]
9. Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors.
Mok K; Wu C; Chan S; Wong G; Wong VW; Ma B; Lui R
Clin Colorectal Cancer; 2024 Mar; 23(1):4-13. PubMed ID: 38172003
[TBL] [Abstract][Full Text] [Related]
10. Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors.
Townsend MJ; Benque IJ; Li M; Grover S
Aliment Pharmacol Ther; 2024 Jun; 59(11):1350-1365. PubMed ID: 38590108
[TBL] [Abstract][Full Text] [Related]
11. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
